Opiant Pharmaceuticals Inc (OPNT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
Aug 11, 2022: Opiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate Update
May 20, 2022: Opiant Pharmaceuticals to Hold Virtual 2022 Annual Shareholder Meeting on Tuesday, June 14, 2022 at 9:00am PDT
May 10, 2022: Opiant Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update
The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Opiant Pharmaceuticals Inc (Opiant), formerly, Lightlake Therapeutics Inc is a specialty pharmaceutical company that develops pharmacological treatments for substance use, addiction, and eating disorders. It focuses on developing treatments to reverse opioid overdoses, alcohol use disorder, acute cannabinoid overdose, and opioid use disorder. The company develops products based on its patented novel opioid antagonist nasal delivery technology. Opiant developed NARCAN (naloxone hydrochloride) nasal spray, a treatment to reverse opioid overdose. The product is approved for marketing in the US by its partner, Adapt Pharma. Opiant is headquartered in Santa Monica, California, the US.Opiant Pharmaceuticals Inc Key Recent Developments
Nov 14, 2022: Opiant Pharmaceuticals Announces Third Quarter 2022 Financial ResultsAug 11, 2022: Opiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate Update
May 20, 2022: Opiant Pharmaceuticals to Hold Virtual 2022 Annual Shareholder Meeting on Tuesday, June 14, 2022 at 9:00am PDT
May 10, 2022: Opiant Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Section 1 - About the Company- Opiant Pharmaceuticals Inc - Key Facts
- Opiant Pharmaceuticals Inc - Key Employees
- Opiant Pharmaceuticals Inc - Key Employee Biographies
- Opiant Pharmaceuticals Inc - Major Products and Services
- Opiant Pharmaceuticals Inc - History
- Opiant Pharmaceuticals Inc - Company Statement
- Opiant Pharmaceuticals Inc - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Company Overview
- Opiant Pharmaceuticals Inc - Business Description
- Business Segment: Grant and Contract revenue
- Performance
- Business Segment: Royalty and Licensing revenue
- Performance
- Business Segment: Treatment Investment revenue
- Performance
- Opiant Pharmaceuticals Inc - Corporate Strategy
- Opiant Pharmaceuticals Inc - SWOT Analysis
- SWOT Analysis - Overview
- Opiant Pharmaceuticals Inc - Strengths
- Opiant Pharmaceuticals Inc - Weaknesses
- Opiant Pharmaceuticals Inc - Opportunities
- Opiant Pharmaceuticals Inc - Threats
- Opiant Pharmaceuticals Inc - Key Competitors
- Financial Ratios - Capital Market Ratios
- Financial Ratios - Annual Ratios
- Performance Chart
- Financial Performance
- Financial Ratios - Interim Ratios
- Financial Ratios - Ratio Charts
- Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
- Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
- Opiant Pharmaceuticals Inc, Recent Deals Summary
- Nov 14, 2022: Opiant Pharmaceuticals Announces Third Quarter 2022 Financial Results
- Aug 11, 2022: Opiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate Update
- May 20, 2022: Opiant Pharmaceuticals to Hold Virtual 2022 Annual Shareholder Meeting on Tuesday, June 14, 2022 at 9:00am PDT
- May 10, 2022: Opiant Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update
- Mar 15, 2022: Opiant Pharmaceuticals Announces Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
- Nov 11, 2021: Opiant Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update
- Nov 02, 2021: Opiant announces publication of manuscript treatment of overdose in the synthetic opioid era in peer-reviewed journal Pharmacology & Therapeutics
- Aug 25, 2021: Opiant Pharmaceuticals to Participate in September Investor Conferences
- Jul 12, 2021: Opiant Pharmaceuticals Announces Appointment of Matthew Ruth as Chief Commercial Officer
- May 18, 2021: Opiant Pharmaceuticals to Hold Virtual 2021 Annual Shareholder Meeting on Tuesday, June 15, 2021 at 9:00am PDT
- Methodology
- Ratio Definitions
- About the Publisher
- Contact the Publisher
- Disclaimer
- Opiant Pharmaceuticals Inc, Key Facts
- Opiant Pharmaceuticals Inc, Key Employees
- Opiant Pharmaceuticals Inc, Key Employee Biographies
- Opiant Pharmaceuticals Inc, Major Products and Services
- Opiant Pharmaceuticals Inc, History
- Opiant Pharmaceuticals Inc, Subsidiaries
- Opiant Pharmaceuticals Inc, Key Competitors
- Opiant Pharmaceuticals Inc, Ratios based on current share price
- Opiant Pharmaceuticals Inc, Annual Ratios
- Opiant Pharmaceuticals Inc, Interim Ratios
- Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
- Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2016 to YTD 2022
- Opiant Pharmaceuticals Inc, Recent Deals Summary
- Currency Codes
- Capital Market Ratios
- Equity Ratios
- Profitability Ratios
- Cost Ratios
- Liquidity Ratios
- Leverage Ratios
- Efficiency Ratios
- Opiant Pharmaceuticals Inc, Performance Chart (2017 - 2021)
- Opiant Pharmaceuticals Inc, Ratio Charts
- Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2016 to YTD 2022
- Opiant Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2016 to YTD 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Camurus AB
- BioDelivery Sciences International Inc
- Orexo AB
- Avalo Therapeutics Inc
- Shire Pharmaceuticals International UC
- Alkermes Plc
- BioCorRx Inc
- H. Lundbeck AS
- Indivior Plc
- Shire Pharmaceuticals International UC
- Orexo AB
- Indivior Plc
- H. Lundbeck AS
- Camurus AB
- BioDelivery Sciences International Inc
- BioCorRx Inc
- Avalo Therapeutics Inc
- Alkermes Plc
